Active Movers: ArcelorMittal SA (ADR) (NYSE:MT), Valeant Pharmaceuticals Intl Inc (NYSE:VRX)

On Thursday, Shares of ArcelorMittal SA (ADR) (NYSE:MT), added 2.01% and closed at $7.10 in the last trading session. The last trading range of the stock ranges between $6.95 and $7.32. The company’s Market capitalization is $24.37 Billion with the total Outstanding Shares of 2.14 billion. ArcelorMittal is expanding its global portfolio of automotive steels by introducing a new generation of advanced high strength steels (AHSS). These innovative steels include the launch of new press hardfacilitate steels (PHS) Ductibor® 1000 and Usibor® 2000 – both of which are already available for OEM qualification testing in Europe – and martensitic steels MartINsite® M1700 and M2000. The company is also preparing to expand its family of third generation advanced high strength steel (3G AHSS), which presently includes Fortiform® 1050 in Europe, starting in 2017. Together, these new steel grades will assist automakers further reduce body-in-white weight to improve fuel economy without compromising vehicle safety or performance.

Technical Analysis: During the 52-week trading session the minimum price at which share price traded, registered at $2.93 and reached to max level of $7.32. The EPS of company is strolling at -3.05.

Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), jumped 4.54% and closed at $16.82 in the last trading session. The last trading range of the stock ranges between $16.04 and $17.00. The company’s Market capitalization is $6.14 Billion with the total Outstanding Shares of 347.67 million. Pharming Group N.V. (the “Company”) (PHARM.AS) recently declared that following evaluation of a dossier presented by the Company earlier this year, the Committee for Medicinal Products for Human Use (CHMP), an advisory committee of the European Medicine Agency (EMA), has adopted a positive opinion recommending an extension to the terms of the marketing authorisation for RUCONEST® to the European Commission. This recommendation will allow self-administration of RUCONEST® for acute hereditary angioedema (HAE) attacks by adolescents and adults with a new custom-designed administration kit. Following normal timelines after the adoption of the positive opinion by CHMP, the final decision from the European Committee is expected in January 2017. It is expected that the kits will become available for use in the various EU markets soon thereafter.

Technical Analysis: During the 52-week trading session the minimum price at which share price traded, registered at $13.77 and reached to max level of $119.87. The EPS of company is strolling at -6.48.

Leave a Reply

Your email address will not be published. Required fields are marked *